Bicycle Therapeutics Croissance future
Future contrôle des critères 2/6
Bicycle Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 2.4% et de 57% par an respectivement. Le BPA devrait croître de de 10.2% par an. Le rendement des capitaux propres devrait être -48.1% dans 3 ans.
Informations clés
2.4%
Taux de croissance des bénéfices
10.2%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 28.4% |
| Taux de croissance des recettes | 57.0% |
| Rendement futur des capitaux propres | -48.1% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
Nov 07Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 50 | -284 | -232 | -193 | 12 |
| 12/31/2025 | 32 | -244 | -211 | -168 | 13 |
| 12/31/2024 | 37 | -178 | -179 | -129 | 13 |
| 9/30/2024 | 37 | -166 | -204 | -203 | N/A |
| 6/30/2024 | 40 | -165 | -165 | -164 | N/A |
| 3/31/2024 | 42 | -168 | -86 | -85 | N/A |
| 12/31/2023 | 27 | -181 | -64 | -61 | N/A |
| 9/30/2023 | 25 | -162 | -48 | -44 | N/A |
| 6/30/2023 | 23 | -140 | -55 | -48 | N/A |
| 3/31/2023 | 15 | -124 | -122 | -106 | N/A |
| 12/31/2022 | 14 | -113 | -105 | -86 | N/A |
| 9/30/2022 | 15 | -101 | -85 | -66 | N/A |
| 6/30/2022 | 16 | -87 | -54 | -39 | N/A |
| 3/31/2022 | 14 | -78 | -34 | -27 | N/A |
| 12/31/2021 | 12 | -67 | -17 | -15 | N/A |
| 9/30/2021 | 12 | -66 | -22 | -21 | N/A |
| 6/30/2021 | 11 | -62 | -54 | -53 | N/A |
| 3/31/2021 | 11 | -56 | -54 | -53 | N/A |
| 12/31/2020 | 10 | -51 | -19 | -18 | N/A |
| 9/30/2020 | 12 | -38 | -7 | -6 | N/A |
| 6/30/2020 | 9 | -37 | -8 | -7 | N/A |
| 3/31/2020 | 9 | -35 | -4 | -2 | N/A |
| 12/31/2019 | 14 | -31 | -30 | -29 | N/A |
| 9/30/2019 | 10 | -33 | -34 | -33 | N/A |
| 6/30/2019 | 11 | -31 | -28 | -26 | N/A |
| 3/31/2019 | 11 | -26 | -25 | -24 | N/A |
| 12/31/2018 | 7 | -22 | -27 | -26 | N/A |
| 9/30/2018 | 7 | -21 | -20 | -19 | N/A |
| 12/31/2017 | 2 | -16 | N/A | -1 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: BCYC devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: BCYC devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: BCYC devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de BCYC ( 57% par an) devrait croître plus rapidement que le marché US ( 9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de BCYC ( 57% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: BCYC devrait être non rentable dans 3 ans.